1. Articles from ncbi.nlm.nih.gov

  2. 25-48 of 1681 « 1 2 3 4 5 ... 68 69 70 »
    1. Predicting survival times for neuroblastoma patients using RNA-seq expression profiles.

      Predicting survival times for neuroblastoma patients using RNA-seq expression profiles.

      Biol Direct. 2018 May 30;13(1):11

      Authors: Grimes T, Walker AR, Datta S, Datta S

      Abstract BACKGROUND: Neuroblastoma is the most common tumor of early childhood and is notorious for its high variability in clinical presentation. Accurate prognosis has remained a challenge for many patients. In this study, expression profiles from RNA-sequencing are used to predict survival times directly.

      Read Full Article
    2. Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Pediatr Blood Cancer. 2018 May 24;:e27229

      Authors: Chen K, Cai Y, Zhang M, Wu Z, Wu Y

      Abstract BACKGROUND: Neuroblastoma is one of the most common pediatric solid tumors. Although the 5-year overall survival rate has increased over the past few decades, high-risk patients still have a poor prognosis due to a lack of biomonitoring therapy.

      Read Full Article
    3. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

      Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 May 24;:e27257

      Authors: Lee JW, Son MH, Cho HW, Ma YE, Yoo KH, Sung KW, Koo HH

      Abstract BACKGROUND: This study investigated the clinical significance of MYCN amplification within high-risk neuroblastoma (NB). METHODS: Medical records of 135 patients who were diagnosed with high-risk NB from 2004 to 2016 were reviewed.

      Read Full Article
      Mentions: MYCN NSE
    4. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      Am J Surg Pathol. 2018 May 22;:

      Authors: Xie Y, Xu H, Fang F, Li Z, Zhou H, Pan J, Guo W, Zhu X, Wang J, Wu Y

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in children with contrasting outcomes. Precise risk assessment contributes to prognosis prediction, which is critical for treatment strategy decisions.

      Read Full Article
      Mentions: Treatment
    5. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.

      MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.

      Biol Res. 2018 May 24;51(1):13

      Authors: Wu T, Lin Y, Xie Z

      Abstract BACKGROUND: Neuroblastoma (NB) represents the most common extracranial solid tumor in children. Accumulating evidence shows that microRNAs (miRs) play an important role in the carcinogenesis of NB. Here, we investigated the biological function of miR-1247 in NB in vitro.

      Read Full Article
    6. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clin Cancer Res. 2018 May 21;:

      Authors: Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, Sondel PM, Seeger RC, Maris JM, Khan J

      Read Full Article
      Mentions: MYCN
    7. Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

      Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

      Oncotarget. 2018 Apr 24;9(31):22184-22193

      Authors: Ram Kumar RM, Schor NF

      Abstract Neuroblastoma (NB), a developmental cancer, is often fatal, emphasizing the need to understand its pathogenesis and identify new therapeutic targets.

      Read Full Article
    8. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

      Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

      Sci Transl Med. 2018 May 16;10(441):

      Authors: Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC

      Read Full Article
      Mentions: MYCN
    9. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    10. Cancer Treatment and End-of-Life Care.

      Cancer Treatment and End-of-Life Care.

      J Palliat Med. 2018 May 16;:

      Authors: Sinha S, Matharu JK, Jacob J, Palat G, Brun E, Wiebe T, Segerlantz M

      Abstract AIM: To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India.

      Read Full Article
    11. PHOX2B Is A Reliable Immunomarker in Distinguishing Peripheral Neuroblastic Tumors From CNS Embryonal Tumors.

      PHOX2B Is A Reliable Immunomarker in Distinguishing Peripheral Neuroblastic Tumors From CNS Embryonal Tumors.

      Histopathology. 2018 May 14;:

      Authors: Alexandrescu S, Paulson V, Dubuc A, Ligon A, Lidov HG

      Abstract INTRODUCTION: The PHOX2B gene regulates neuronal maturation in the brain stem nuclei associated with cardiorespiratory function, and in the autonomic sympathetic and enteric nervous system.

      Read Full Article
      Mentions: MYCN PHOX2B
    12. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

      MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

      Oncotarget. 2018 Apr 17;9(29):20323-20338

      Authors: Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, Koster J, Perini G, Coarfa C, Shohet JM

      Abstract The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    13. Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      J Pediatr Surg. 2018 Apr 14;:

      Authors: Campagna G, Rosenfeld E, Foster J, Vasudevan S, Nuchtern J, Kim E, Commander S, Naik-Mathuria B

      Abstract BACKGROUND/PURPOSE: To compare the adequacy and safety of percutaneous core needle biopsy and surgical wedge biopsy of neuroblastoma in children.

      Read Full Article
      Mentions: Treatment Biopsy
    14. Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Surgery. 2018 May 09;:

      Authors: Subramanian C, White PT, Kuai R, Kalidindi A, Castle VP, Moon JJ, Timmermann BN, Schwendeman A, Cohen MS

      Read Full Article
      Mentions: Surgery
    15. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      BMC Cancer. 2018 May 11;18(1):560

      Authors: Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M

      Abstract BACKGROUND: Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal.

      Read Full Article
    16. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Oncol Rep. 2018 May 08;:

      Authors: Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G, Song L

      Read Full Article
      Mentions: Chemotherapy
    17. Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Mol Med Rep. 2018 May 02;:

      Authors: Mei Z, Yan P, Wang Y, Liu S, He F

      Abstract Neuroblastoma is one of the leading causes of cancer‑associated mortality worldwide, particularly in children, partially due to the absence of effective therapeutic targets and diagnostic biomarkers.

      Read Full Article
    18. NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived Sk‑n‑as cells via the activation of β1 integrin expression.

      NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived SK‑N‑AS cells via the activation of β1 integrin expression.

      Int J Oncol. 2018 May 07;:

      Authors: Ishizuka Y, Koshinaga T, Hirano T, Nagasaki-Maeoka E, Watanabe Y, Hoshi R, Yoshizawa S, Sugito K, Kawashima H, Uekusa S, Fukuda N, Soma M, Fujiwara K

      Read Full Article
    19. Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.

      Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.

      Mol Med Rep. 2018 May 03;:

      Authors: Wang Y, Gao S, Wang W, Xia Y, Liang J

      Abstract Neuroblastoma, one of the most common types of cancer in childhood, is commonly treated with surgery, radiation and chemotherapy. However, prognosis and survival remain poor for children with high‑risk neuroblastoma. Therefore, the identification of novel, effective therapeutic targets is necessary.

      Read Full Article
    20. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.

      Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.

      Pediatr Hematol Oncol. 2018 May 08;:1-10

      Authors: Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB

      Read Full Article
      Mentions: MYCN NSE
    21. Predicting neuroblastoma using developmental signals and a logic-based model.

      Predicting neuroblastoma using developmental signals and a logic-based model.

      Biophys Chem. 2018 Apr 30;238:30-38

      Authors: Kasemeier-Kulesa JC, Schnell S, Woolley T, Spengler JA, Morrison JA, McKinney MC, Pushel I, Wolfe LA, Kulesa PM

      Abstract Genomic information from human patient samples of pediatric neuroblastoma cancers and known outcomes have led to specific gene lists put forward as high risk for disease progression.

      Read Full Article
    22. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    23. miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      Oncotarget. 2018 Apr 10;9(27):19014-19025

      Authors: Stigliani S, Morandi F, Persico L, Lagazio C, Erminio G, Scaruffi P, Corrias MV

      Read Full Article
      Mentions: Bone Marrow
    25-48 of 1681 « 1 2 3 4 5 ... 68 69 70 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video